According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.